Literature DB >> 31604650

Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: Transforaminal versus conventional approach.

Sara Bortolani1, Guido Stura2, Giancarlo Ventilii2, Liliana Vercelli1, Enrica Rolle1, Federica Ricci3, Mauro Bergui2, Tiziana Mongini4.   

Abstract

Spinal deformities and surgical correction of scoliosis can make intrathecal delivery of nusinersen very challenging. We aim to evaluate the feasibility and safety of intrathecal administration of nusinersen either via interlaminar or transforaminal approach in a cohort of adult and adolescent patients with spinal muscular atrophy (SMA). Twelve patients were treated with nusinersen in our center under CT-guidance; after a CT scan of the lumbar column, we identified a safe virtual trajectory for the needle and defined patients to address to the transforaminal approach (seven patients) or the interlaminar approach (five patients). Out of 47 procedures, all injections but one were successful. There was one adverse event (post-lumbar puncture syndrome) in the interlaminar approach group (out of 20 procedures) and four adverse events in TFA group (out of 27 procedures) including one serious adverse event, a subarachnoid hemorrhage that required hospitalization. Transforaminal approach can be considered an effective option for nusinersen administration but potentially associated with serious complications, therefore it should be recommended in very selected patients.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CT-guide; Intrathecal; Nusinersen; Spinal muscular atrophy

Year:  2019        PMID: 31604650     DOI: 10.1016/j.nmd.2019.08.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

1.  Scoliosis Orthopedic Surgery Combined With Nusinersen Intrathecal Injection Significantly Improved the Outcome of Spinal Muscular Atrophy Patient: A Case Report.

Authors:  Beiyu Xu; Cuijie Wei; Xiao Hu; Wenzhu Li; Zhen Huang; Chengli Que; Jianxing Qiu; Chunde Li; Hui Xiong
Journal:  Front Neurol       Date:  2022-04-25       Impact factor: 4.086

Review 2.  Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.

Authors:  Flavien Bizot; Adeline Vulin; Aurélie Goyenvalle
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

3.  A Systematic Review of Procedural Complications from Transforaminal Lumbar Puncture for Intrathecal Nusinersen Administration in Patients with Spinal Muscular Atrophy.

Authors:  A Grayev; M Schoepp; A Kuner
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-25       Impact factor: 4.966

4.  Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy.

Authors:  Alma Osmanovic; Gresa Ranxha; Susanne Petri; Olivia Schreiber-Katz; Mareike Kumpe; Lars Müschen; Camilla Binz; Flavia Wiehler; Lejla Paracka; Sonja Körner; Katja Kollewe
Journal:  J Neurol       Date:  2020-05-02       Impact factor: 4.849

5.  Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review.

Authors:  Hamish W Y Wan; Kate A Carey; Arlene D'Silva; Steve Vucic; Matthew C Kiernan; Nadine A Kasparian; Michelle A Farrar
Journal:  Orphanet J Rare Dis       Date:  2020-03-12       Impact factor: 4.123

6.  Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy.

Authors:  Alma Osmanovic; Gresa Ranxha; Mareike Kumpe; Claudia D Wurster; Benjamin Stolte; Isabell Cordts; René Günther; Maren Freigang; Lars H Müschen; Camilla Binz; Andreas Hermann; Marcus Deschauer; Paul Lingor; Albert C Ludolph; Tim Hagenacker; Olivia Schreiber-Katz; Susanne Petri
Journal:  Ther Adv Neurol Disord       Date:  2021-03-05       Impact factor: 6.570

7.  Ultra-low radiation dose protocol for CT-guided intrathecal nusinersen injections for patients with spinal muscular atrophy and severe scoliosis.

Authors:  Grzegorz Rosiak; Anna Lusakowska; Krzysztof Milczarek; Dariusz Konecki; Anna Fraczek; Olgierd Rowinski; Anna Kostera-Pruszczyk
Journal:  Neuroradiology       Date:  2021-01-29       Impact factor: 2.804

8.  Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases.

Authors:  Anja Holm; Stine N Hansen; Henrik Klitgaard; Sakari Kauppinen
Journal:  RNA Biol       Date:  2021-12-31       Impact factor: 4.766

9.  Ultrasound-guided nusinersen administration for spinal muscular atrophy patients with severe scoliosis: an observational study.

Authors:  Jiao Zhang; Xulei Cui; Si Chen; Yi Dai; Yuguang Huang; Shuyang Zhang
Journal:  Orphanet J Rare Dis       Date:  2021-06-13       Impact factor: 4.123

10.  Clinical effects of transforaminal approach vs interlaminar approach in treating lumbar disc herniation: A clinical study protocol.

Authors:  Wei Chen; Yong Zheng; Guiqing Liang; Guangfu Chen; Yabin Hu
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.